

IN THE UNITED STATES RECEIVING OFFICE (RO/US)  
Designated/Elected Office (DO/EO/US)

U.S. National Stage of  
International Application No.: PCT/GB2004/001054  
International Filing Date: March 12, 2004  
Earliest Priority Date: March 14, 2003  
Applicants: Anders Hallberg, Wesley Schaal, Mats Larhed, Kristofer  
Olofsson, Benjamin Pelcman and Andrei Sanin  
Title: PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF  
INFLAMMATION  
Attorney's Docket No.: 3951.1000-000

Date: <u>11/23/05</u>
EXPRESS MAIL LABEL NO. <u>EV 214879528 US</u>

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:  
☐ a Statement under 37 CFR 1.97(e), as checked below, or  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:  
☐ a Statement under 37 CFR 1.97(e), as checked below, and  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application  
filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)  
Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
  - ☒ Copies of the cited references [B1 through B21, C1 and C2] are enclosed.
  - ☐ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
  - ☒ The listed references [B10 and C2] were cited in the enclosed International Search Report in a counterpart foreign application.
  - ☒ The "concise explanation" requirement (non-English references) under 37 CFR 1.98(a)(3) is satisfied by:
    - ☐ the explanation provided on the attached sheet.
    - ☐ the explanation provided in the Specification.
    - ☐ submission of the enclosed International Search Report.
    - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
  - ☒ the enclosed English language abstract - for References B4 (JP 03142277), B5 (JP 10193801) (B4 and B5 abstracts obtained from espacenet.com), B15 and B16.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Steven G. Davis, Esq.  
Registration No.: 39,652  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

*November 23 2005*

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  November 23, 2005  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3951.1000-000	U.S. Nat'l Stage of Int'l Application No. PCT/GB2004/001054	
	FIRST NAMED INVENTOR Anders Hallberg		FILING DATE March 12, 2004
	EXAMINER Not Assigned	CONFIRMATION NO. Not Assigned	GROUP Not Assigned

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1	5,258,397	11-02-1993	Lepage, <i>et al.</i>
	A2	5,665,737	09-09-1997	Cavalla, <i>et al.</i>
	A3	6,372,770 B1	04-16-2002	Chasin, <i>et al.</i>
	A1	6,653,304 B2	11-25-2003	Leftheris, <i>et al.</i>
	A5	2004/0192667 A1	09-30-2004	Makriyannis, <i>et al.</i>
	A6	2004/0204406 A1	10-14-2004	Nazare, <i>et al.</i>
	A7	2005/0049237 A1	03-03-2005	Atkinson, <i>et al.</i>

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	B1	EP 0 937 459 A2	08-25-1999	Sumitomo Pharmaceuticals Co., Ltd.	
	B2	EP 1 433 788 A1	06-30-2004	Aventis Pharma Deutschland GmbH	
	B3	EP 1 479 678 A1	11-24-2004	Aventis Pharma Deutschland GmbH	
	B4	JP 03142277	06-18-1991	Fuji Photo Film Co. Ltd.	X
	B5	JP 10193801	07-28-1998	Fuji Photo Film Co. Ltd.	X
	B6	WO 93/23040	11-25-1993	Merck & Co., Inc.	
	B7	WO 93/23040	11-25-1993	Merck & Co., Inc.	
	B7	WO 95/00491	01-05-1995	Dunlana Pty., Ltd.	
	B9	WO 96/11917	04-25-1996	Euroceltique, S.A.	
	B10	WO 99/25695	05-27-1999	FujiSawa Pharmaceutical, Co., Ltd.	
	B11	WO99/29672	06-17-1999	Eli Lilly and Company	
	B12	WO 01/57024 A1	08-09-2001	University College London	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  November 23, 2005  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3951.1000-000		U.S. Nat'l Stage of Int'l Application No. PCT/GB2004/001054	
	FIRST NAMED INVENTOR Anders Hallberg		FILING DATE March 12, 2004	
	EXAMINER Not Assigned	CONFIRMATION NO. Not Assigned	GROUP Not Assigned	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B13	WO 01/58869 A2	08-16-2001	Bristol-Meyers Squibb Company		
	B14	WO 02/00651 A2	01-03-2002	DuPont Pharmaceuticals Company		
	B15	WO 02/062770 A1	08-15-2002	Kumiai Chemical Industry, Co., Ltd.		X
	B16	WO 02/24656 A1	03-28-2002	Nihon Nohyaku, Co., Ltd.		X
	B17	WO 03/020217 A2	03-13-2003	University of Connecticut		
	B18	WO 03/037274 A2	05-08-2003	Icagen, Inc.		
	B16	WO 03/068767 A1	08-21-2003	Icagen, Inc.		
	B20	WO 2004/056815 A1	07-08-2004	Aventis Pharma Deutschland GmbH		
	B21	WO 2005/012256 A1	02-10-2005	Astex Technology Limited		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C1	Goel, A., <i>et al.</i> , "Structure - Activity Study on Antiinflammatory Pyrazole Carboxylic Acid Hydrazide Analogs Using Molecular Connectivity Indices," <i>J. Chem. Inf. Comput. Sci.</i> , 35:510-514 (1995).	
C2	Tihanyi, E., <i>et al.</i> , "Pyrazolecarboxylic Acid Hydrazides As Antiinflammatory Agents. New Selective Lipxygenase Inhibitors," <i>Eur. J. Med. Chem. - Chim. Ther.</i> , 19(5): 433-439 (1984).	

EXAMINER	DATE CONSIDERED
----------	-----------------